Nav: Home

New vaccine offers fresh take on malaria fight

January 23, 2019

Early research on a new approach to protecting against malaria is offering promising, potentially long-lasting results against the persistent parasite that sickens hundreds of millions people each year.

The approach uses a cytomegalovirus-based platform that's already being used in vaccines being developed to battle HIV and tuberculosis. This new vaccine reduced the malaria-causing parasite's release from the liver and into the blood of infected rhesus macaques by 75 to 80 percent, reports a paper published in the journal PLOS ONE.

"The problem with most vaccines is that their effectiveness is often short-lived," said the study's lead author, Klaus Früh, Ph.D., of OHSU's Vaccine & Gene Therapy Institute and a professor of molecular and cellular biosciences at the OHSU School of Medicine. "Our cytomegalovirus-based vaccine platform can create and keep immunity for life. With further research and development, it could offer a lifetime of protection against malaria."

Malaria is a serious and sometimes fatal disease caused by Plasmodium parasites, which are spread to humans through mosquito bites. It can cause high fevers, shaking chills, flu-like illness and, in the worst cases, death. Worldwide, 216 million people were infected with malaria in 2016, leading to 445,000 deaths. The vast majority of infections occur in Africa.

The decades-long search for an effective malaria vaccine has been challenging. The World Health Organization is using one vaccine - known as RTS,S/AS01 or by its brand name, Mosquirix - as part of new, routine vaccination programs in three African countries. But RTS,S has been shown to only reduce malaria transmission in kids - in whom malaria is most often fatal - by 39 percent four years after it was administered. Its efficacy was further reduced to 4.4 percent seven years afterward. Vaccines against viruses and bacteria typically have protection rates of more than 90 percent.

Vaccine makeover

Most vaccines are designed to encourage the human body to respond to invading, disease-causing pathogens by creating antibodies that disable those pathogens. OHSU's new vaccine takes a different approach by using a weakened form of a common herpes virus - cytomegalovirus, or CMV - that infects most people without causing disease.

Früh and his colleagues weave tiny bits of their target pathogen into CMV. Those who receive the resulting, re-engineered CMV vaccine produce memory T-cells that can search for and destroy pathogen-infected cells. Studies have shown this approach enables vaccinated nonhuman primates to develop and maintain a high state of immunity years later.

The CMV vaccine platform has been licensed by Vir Biotechnology, Inc., of San Francisco, which plans to lead a human clinical trial for a CMV-based HIV vaccine in 2019. The same basic platform is also being used in a new TB vaccine, and is now the basis for this malaria vaccine.

Nuts & bolts

Früh and his colleagues pursued a malaria vaccine because they noticed the memory T-cells their CMV-based vaccine produce exist in high concentrations in the liver, where the malaria parasite hides out shortly after infecting a human.

They developed two different versions of their CMV-based malaria vaccine while using four different proteins made by the Plasmodium parasite. The resulting vaccines delayed the parasite's appearance in the blood of 16 infected and vaccinated rhesus macaques by eliminating between 75 and 80 percent of parasites from the liver. A year later, the vaccinated nonhuman primates still had immunity against malaria, while eight control animals that weren't vaccinated did not.

In an effort to make their vaccine 100 percent protective against malaria, the research team will evaluate 15 different Plasmodium-made proteins for the vaccine. They will also examine combining their CMV-based vaccine with other experimental vaccines or the existing RTS,S vaccine.
-end-
The study was a collaboration between OHSU, the Naval Medical Research Center, National Institutes of Health and Fred Hutchinson Cancer Research Center. Früh conducted the study with animals at OHSU's Oregon National Primate Research Center.

This research was supported by the Military Infectious Diseases Research Program (grant F0351_12_NM) and the National Institutes of Health (grants R21AI103498, RO1AI059457, P511OD011092, R24 RR016001, HHSN 2722000900037C).

In our interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regards to this research, OHSU and Drs. Fruh, Picker and Hansen have a significant financial interest in VIR Biotechnology Inc., a company that may have a commercial interest in the results of this research and technology.

REFERENCE: Scott G. Hansen, Jennie Womack, Isabel Scholz, Andrea Renner, Kimberly A. Edge, Guangwu Xu, Julia C. Ford, Mikayla Grey, Brandyce St. Laurent, John M. Turner, Shannon Planer, Al W. Legasse, Thomas L. Richie, Joao C. Aguiar, Michael K. Axthelm, Eileen D. Villasante, Walter Weiss, Paul T. Edlefsen, Louis J. Picker, Klaus Früh, "Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge," PLOS One, https://doi.org/10.1371/journal.pone.0210252, Jan. 23, 2019, http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210252.

Related OHSU news stories:

Oregon Health & Science University

Related Malaria Articles:

Could there be a 'social vaccine' for malaria?
Malaria is a global killer and a world health concern.
Transgenic plants against malaria
Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.
Fighting malaria through metabolism
EPFL scientists have fully modeled the metabolism of the deadliest malaria parasite.
Should we commit to eradicate malaria worldwide?
Should we commit to eradicate malaria worldwide, asks a debate article published by The BMJ today?
Investigational malaria vaccine shows considerable protection in adults in malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria -- the deadliest form of the disease -- for the duration of the malaria season, according to new findings published in the Feb.
Why malaria mosquitoes like people with malaria
Malaria mosquitoes prefer to feed -- and feed more -- on blood from people infected with malaria.
Malaria superbugs threaten global malaria control
A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.
Considering cattle could help eliminate malaria in India
The goal of eliminating malaria in countries like India could be more achievable if mosquito-control efforts take into account the relationship between mosquitoes and cattle, according to an international team of researchers.
Seasonal malaria chemoprevention in Senegalese children lowers overall malaria burden
Giving preventive antimalarial drugs to children up to age 10 during active malaria season reduced the cases of malaria in that age group and lowered the malaria incidence in adults, according to a randomized trial carried out in Senegal and published in PLOS Medicine by researchers from the Université Cheikh Anta Diop, Senegal, the London School of Hygiene & Tropical Medicine, UK, and other collaborators.
How malaria fools our immune system
OIST researchers reconstruct the 3-D structure of a malaria protein in combination with human antibodies.

Related Malaria Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".